Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor
CA 2380753 C · Owner: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. · Inventors: Daub, Henrik; Prenzel, Norbert; Ullrich, Axel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present description relates to agents methods for growth-factor receptor , activation by modulating the G-protein mediated signal transduction pathway. It is provided the use of a modulator which acts on a growth-factor precursor to inhibit the activation of the extracellular domain of a growth-factor receptor , for the manufacture of a medicament for the prevention or treatment of cancers which are induced by G-protein mediated signal transduction wherein the medicament comprises the modulator in an amount sufficient to inhibit growth-factor receptor activation, wherein the modulator acts on proHB-EGF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 16, 2000 and granted October 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 16, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 16, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.